Login to your account
Don’t have an account?
Create a Free Account
x
Filter:
Filters applied
- CJCA - COVID-19
- EditorialRemove Editorial filter
- Cowan, SimoneRemove Cowan, Simone filter
- Leong-Poi, HowardRemove Leong-Poi, Howard filter
- Marelli, ArianeRemove Marelli, Ariane filter
Publication Date
Please choose a date range between 2020 and 2020.
Author
- Bewick, David1
- Chow, Chi-Ming1
- Clarke, Brian1
- Fordyce, Christopher B1
- Fournier, Anne1
- Gin, Kenneth1
- Gupta, Anil1
- Hardiman, Sean1
- Jackson, Simon1
- Krahn, Andrew1
- Lau, Benny1
- Mansour, Samer1
- Quraishi, Ata Rehman1
- Roifman, Idan1
- Ruel, Marc1
- Sapp, John1
- Singh, Gurmeet1
- Small, Gary1
- Turgeon, Ricky D1
- Virani, Sean1
- Wood, David A1
- Zieroth, Shelley1
1 Results
- Journal News and Commentary
Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence
Canadian Journal of CardiologyVol. 36Issue 8p1180–1182Published online: June 2, 2020- Ricky D. Turgeon
- Shelley Zieroth
- David Bewick
- Chi-Ming Chow
- Brian Clarke
- Simone Cowan
- and others
Cited in Scopus: 3The COVID-19 pandemic invoked the need for prompt guidance and rapid research to address emerging clinical questions. In response to early theoretical concerns regarding the use of renin-angiotensin system (RAS) blockers, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and angiotensin receptor–neprilysin inhibitors (ARNIs) during the COVID-19 pandemic, the Canadian Cardiovascular Society (CCS) and Canadian Heart Failure Society (CHFS) issued guidance to continue these therapies among patients with heart failure and hypertension.
